Breaking News

Trials & Filings in Brief: Oct. 10, 2013

By Gil Roth | October 10, 2013

Alkermes, Chelsea, CirrusGalectin, Gilead, Lundbeck, Otsuka, Medivir, Pergamum and Relyspa

Preclinical
Galectin posts fibrosis . . . read more

Medivir selects neuropathic pain candidate . . . read more

Phase II
Pergamum peptide posts positive results . . . read more

Phase III
Gilead Cuts CLL Study Short After Positive Results  . . . read more

Lundbeck, Otsuka start Alzheimer's trials . . . read more

Relypsa posts positive results for patiromer . . . read more

Filings
Alkermes MDD drug gets fast-track status . . . read more

Chelsea NOH treatment to get advisory review . . . read more

Cirrus receives FDA grant for MDI research . . . read more

blog comments powered by Disqus